# Dose-Ranging Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT00098228** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 686 (actual)

## Conditions studied

- COPD

## Interventions

- **DRUG:** QAB149

## Key facts

- **NCT ID:** NCT00098228
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2004-12
- **Final completion:** 2004-12
- **Target enrollment:** 686 (ACTUAL)
- **Last updated:** 2011-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00098228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00098228, "Dose-Ranging Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00098228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*